Red Blood Cell Membrane-Camouflaged Gold Nanoparticles for Treatment of Melanoma

Lei Zhao, Hongfu Xie, and Ji Li

1Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
2Hunan Key Laboratory of Aging Biology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China

Correspondence should be addressed to Hongfu Xie; xiehongfucsu@163.com

Received 26 July 2022; Revised 14 September 2022; Accepted 21 September 2022; Published 14 October 2022

Copyright © 2022 Lei Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Patients with melanoma have poor response and low long-term survival to conventional cisplatin (CP). Recently, biomimetic nanoparticles have played a significant role in tumor therapy. The purpose of this study was to mechanistically evaluate the effect of red blood cell membrane camouflaged gold nanoparticles loaded with CP (RBCm@AuNPs-CP) on enhancing chemotherapy in melanoma.

Methods. Treated B16-F10 cells with RBCm@AuNPs-CP, the antimelanoma effect in vitro was explored by detecting cell viability, apoptosis rate, level of reactive oxygen species (ROS), and singlet oxygen. RBCm@AuNPs-CP was injected into the melanoma-bearing mice via tail vein, and the target-ability, therapeutic effect, and toxicity were detected in melanoma tumor-bearing mice.

Results. RBCm@AuNPs-CP had an antiproliferation and apoptosis-inducing effect on B16-F10 cells, which might be mediated by oxidative stress of ROS, and its effect was significantly enhanced compared with the CP treatment group. In vivo experiments suggested the same outcome, with better target-ability of RBCm@AuNPs-CP.

Conclusion. The erythrocyte camouflage nanosystem RBCm@AuNPs-CP exhibited well passive tumor target-ability and promoted apoptosis of melanocytes by inducing ROS. RBCm@AuNPs-CP as a novel safe and effective targeted drug delivery system may provide a promising choice for the treatment of melanoma.

1. Introduction

Melanoma is a type of skin cancer caused by melanocytes. The pigment-producing cells are found in tissues such as epidermis, hair follicles, and iris. Melanomas most commonly occur in sun-exposed areas of the skin (such as the chest, neck, and legs), and these can also be found in the eyes and areas of the body that are not exposed to the sunshine. In most countries, the incidence of melanoma has been increasing over the past few decades [1]. Melanoma accounts for only about 1% of skin cancer, far less than other types of skin cancer [2]. Despite rarity, it is the major cause of skin cancer-related death [3]. The poor prognosis of melanoma is mainly due to the high metastatic capacity of melanoma cells [4].

Cisplatin (CP) is a kind of common chemotherapeutic medication for melanoma. It is used to postoperative adjuvant chemotherapy to reduce metastasis of lymph node and improve the survival rate of patients [5]. However, due to the resistance of patients to CP, conventional therapy has a disappointing effect [6]. Besides, CP also has systemic toxicity, including central nervous system damage and nephrotoxicity [7]. All of these factors limit its application in the treatment of melanoma.

Nanoparticles are a type of particles with size between 10 and 100 nm, which make themselves easy to penetrate and retain into the tumor microenvironment (TME) for coming into force. With small volume, high specific surface area, and low toxicity [8, 9], nanoparticles are ideal drug delivery platforms for tumor therapy. Gold nanoparticles (AuNPs) are recognized as safe and effective nanodrug delivery systems, but they are easily cleared by the mononuclear macrophage system in vivo, which might exist low bioavailability or potential hazards [10, 11].
Erythrocyte membrane is a kind of biomimetic membrane that is easy to obtain with excellent biocompatibility. In our study, AuNPs were encapsulated by erythrocyte membrane, with CP efficiently loaded, to construct a nanodrug loading system RBCm@AuNPs-CP. RBCm@AuNPs-CP passively targeted melanoma through permeability and retention (EPR) effect and controlled release of CP. We evaluate the effect and mechanism in treatment of melanoma (Figure 1).

### 2. Method

#### 2.1. Synthesis of RBCm@AuNPs-CP

AuNPs were synthesized according to the method described [9], combining nanoparticles, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), and N-hydroxysuccinimide (NHS) with CP by mixing in borate buffer (50 mM pH 8.8) for 1 hour. CP was then added to the mixture to give a final concentration of 1 μM for Au, 50 μM for CP, 5 mM for EDC, and 10 mM for NHS. Conjugation was performed in the dark at 20°C for 24 h, then filtered through a 2 K MWCO membrane, and washed 3 times with ddH₂O.

Whole blood from heparin-anticoagulated mice (Balb/c-nu, female) was taken, centrifuged at 2500 rpm, and then squeezed back and forth through 200 nm filter for 20 times. The surplus RBCm was centrifuged (2500 rpm for 10 min, 4°C), and the supernatant was discarded, while the RBCm@AuNPs-CP was prepared.

#### 2.2. Characterization of RBCm@AuNPs

The morphology and size of RBCm@AuNPs and AuNPs were observed by transmission electron microscope (TEM) to confirm whether RBCm was encapsulated on the nanoparticles. The size and surface charge of RBCm@AuNPs and AuNPs were detected by Zetasizer Nano ZS (Malvern Nano series, Malvern, UK). Polyacrylamide gel electrophoresis (SDS-PAGE) was used to detect the proteins on RBCm@AuNPs, RBCm, AuNPs, and RBCm@AuNPs to verify whether RBCm@AuNPs completely retained the whole surface proteins of RBCm.

#### 2.3. CP Loading and Releasing of RBCm@AuNPs

1 mL of RBCm@AuNPs-CP (CP 50 μM) was placed in the dialysis membrane, placed in 20 mL of PBS with pH 7.4 and pH 5.4, respectively, and dialyzed at 37°C for 1, 2, 3, 4, 6, 8, 12, 24, and 48 h; the dialysate was collected; and the concentration of CP in the dialysate was detected to calculate the cumulative release rate of RBCm@AuNPs-CP at different pH. The concentration of CP was detected by microplate reader EnSpire 2300 Multilabel Plate Reader (Waltham, MA) at 300 nm and calculated by the standard curve. The encapsulation efficiency (EE) and loading efficiency (LE) of the calculated drug of RBCm@AuNPs-CP were calculated by the following formulas.

#### 2.4. Antiphagocytic Ability of RBCm@AuNPs

The in vitro immune evasion ability of RBCm@AuNPs was detected. First, AuNPs and Rhodamine B (RhoB) were mixed and stirred overnight, washed 3 times with PBS, and then resuspended. RAW264.7 was plated in a 6-well plate, about 3 × 10⁵ cells per well, and RBCm@AuNPs-RhoB was added. After coincubating RAW 264.7 cells for 4 h, Hoechst 33342 was used to stain the nuclei, confocal microscopy (CLSM) (LSM 800, Carl Zeiss, Oberkochen, Germany) was used to observe the phagocytosis of RBCm@AuNPs-RhoB, and flow cytometry (FCM) (FACScantoTM II, BD, USA) was used to calculate the fluorescence intensity.

#### 2.5. Biocompatibility of RBCm@AuNPs

The hemolysis rate of RBCm@AuNPs was detected to reflect their compatibility in blood. Different concentrations of RBCm@AuNPs (3.125 to 100 μg/ml) were mixed with 5% mouse erythrocyte suspension and incubated at 37°C for 2 h. Centrifuge at 3500 rpm for 5 min, took the supernatant to measure its absorbance at 545 nm with microplate reader, and then added ultrapure water and PBS as positive and negative controls.

The hemolytic rate was calculated as follows:

\[
\text{Hemolytic rate} = \frac{(\text{experimental sample} - \text{negative control A})}{(\text{positive control A} - \text{negative control A})} \times 100\%.
\]

#### 2.6. In Vitro Target-Ability of RBCm@AuNPs

To explore the in vitro targeting ability of RBCm@AuNPs, the B16-F10 Cells uptake experiment was executed. B16-F10 cells were plated in a 6-well plate, about 3 × 10⁵ cells per well, and AuNPs-RhoB and RBCm@AuNPs-RhoB were added. After coincubating B16-F10 cells for 24 h, confocal microscopy (CLSM) (LSM 800, Carl Zeiss, Oberkochen, Germany) was used to observe the fluorescence of RBCm@AuNPs-RhoB in cells, and flow cytometry (FCM) (FACScantoTM II, BD, USA) was used to calculate the fluorescence intensity.

#### 2.7. Evaluation of In Vitro Antimelanoma Effects of RBCm@AuNPs

The cytotoxicity of RBCm@AuNPs-CP on B16-F10 cells was detected by CCK-8, treated with PBS, AuNPs, CP, AuNPs-CP, and RBCm@AuNPs-CP for 24 h, respectively. The concentration of CP in each group was calculated using the following equation:

\[
\frac{R \times 100\%}{L} = \frac{Rf}{Ri} \times 100\%.
\]
was 0.3 μM, and the cell viability in each treatment group was calculated.

In order to further prove the in vitro anti-tumor effect of RBCm@AuNPs-CP, Annexin V-FITC/PI apoptosis detection kit was used to detect the apoptosis of B16-F10 cells in each group after 24 h treatment. The cells were plated in small culture flasks (1 × 10^6/flask), and the above treatments were added, respectively. After 24 hours of digestion with EDTA-free trypsin, the cell suspension was taken and centrifuged at 1000 g for 5 min, the supernatant was discarded, and 195 μL Annexin was added. The cells were gently resuspended in V-FITC binding solution, 5 μL Annexin V-FITC staining solution was added, 10 μL PI was added and mixed, and the apoptosis of cells was analyzed by FCM.

2.8. ROS and Singlet Oxygen Levels Detected. B16-F10 cells were seeded in 6-well plates, and the cells were collected 24 hours after adding each treatment group. After washing 3 times with PBS, adding DCFH-DA, incubating at 37°C for 20 minutes, and washing three times, the level of ROS was detected by FCM.

The singlet oxygen detection kit was used in above treated cells, and the expression level of singlet oxygen was observed under the CLSM.

2.9. Construction of Melanoma-Bearing Mice. 6-8-week-old BALB/c-nu mice were adaptively fed for 1 week at an SPF animal breeding center. The B16-F10 cells cultured in vitro were digested, washed, and resuspended to obtain a cell suspension. Cell suspensions were injected into the subcutaneous tissue of the legs of nude mice at an injection volume of 1 × 10^6/cell. The tumor was observed, and the tumor size was measured every other day. All animal procedures were approved by the Animal Welfare and Research Ethics Committee of Xiangya Hospital.

2.10. In Vivo Target-Ability of RBCm@AuNPs. The AuNPs and RBC@AuNPs were mixed with Cy-5 and stirred for 24 h, and the unbound Cy-5 was removed using a 2KD dialysis bag. On the 10th day, tumor-bearing Cy-5-labeled AuNPs and RBC@AuNPs were injected into B16-F10 tumor-bearing mice through the tail vein. Tumor-bearing mice were anesthetized with isoflurane after 6 h and 24 h, respectively, and the distribution of AuNPs and RBC@AuNPs in mice was detected on Xenogen IVIS lumina XR imaging system (Caliper Life Science, USA). After 48 hours, the tumor-bearing mice were euthanized. The tumor, heart, liver, spleen, lung, and kidney were removed, and the fluorescence intensity of AuNPs and RBC@AuNPs in the tumor site of each tissue was detected by the XR imaging system, respectively.

2.11. In Vivo Antimelanoma Ability of RBCm@AuNPs. When the tumor volume was about 100 mm³, it was recorded as day 0 (D0), and they were randomly divided into 5 groups (n = 3 per group) by tail vein injection of PBS, AuNPs, CP, AuNPs-CP, and RBCm@AuNPs-CP, in which the dose of CP was 10 μmol/kg/d, once a day for 3 consecutive days. Tumor size and mouse body weight were recorded every other day, and all animals were anesthetized and euthanized on day 14 (D14). Anticoagulated whole blood, tumors, and major organs (heart, liver, spleen, lung, and kidney) were collected. The major organs and tumors were fixed with 4% paraformaldehyde, then paraffin-embedded and then stained with H&E.

3. Results

3.1. Construction and Characterization of RBCm@AuNPs-CP. As shown in Figures 2(a) and 2(b), AuNPs were spherical nanoparticles with the size of 45.3 ± 12.34 nm and zeta potential of −42.1 ± 6.3 mV, which showed well dispersion and uniformity. Red blood cell membrane vesicles (RBCm)
were 156.1 ± 18.3 nm with zeta potential of −27.3 ± 2.0 mV. The size of the erythrocyte membrane-coated gold nanoparticles (RBCm@AuNPs) synthesized was 181.4 ± 16.1 nm, while zeta potential was −29.1 ± 2.6 mV. The increase in size and potential indicated that the erythrocyte membrane was successfully encapsulated. The same results could also be observed in the TEM image, where multiple AuNPs were encapsulated in the RBCm.

From the SDS-PAGE test (Figure 2(c)), it could be found that RBCm@AuNPs and RBCm had the same protein bands, indicating that the synthesized RBCm@AuNPs retain the integrated protein on RBCm, which provided the possibility of good biocompatibility.

3.2. Drug Loading and Release of RBCm@AuNPs. As shown in Figure 3(a), the EE of RBCm@AuNPs loaded with CP was 88.2 ± 4.6%, and LE was 158.3 ± 21.4%, indicating a high loading efficiency. Figure 3(b) showed the drug release curves of the nanoplatforms at different time points. After AuNPs-CP was incubated in the buffer at pH 7.4 and pH 5.4 for 48 h, the release rates of CP were 17.6 ± 2.1% and 79.8 ± 5.4%, respectively; the release rates of RBCm@AuNPs-CP in the pH 7.4 and pH 5.4 buffers at 48 h were 18.2 ± 1.9% and 77.3 ± 10.0%, respectively. The AuNPs-CP after erythrocyte membrane camouflaged (RBCm@AuNPs-CP group) was no significant different from AuNPs-CP on the release of CP. RBCm@AuNPs-CP released a little drug in the normal physiological status (pH 7.4), while released mounts of CP in the acidic microenvironment as melanoma (pH 5.4), which was significantly increased. The RBCm@AuNPs-CP constructed in this study could efficiently transport CP to melanoma and achieve the goals of controlled release.

3.3. Antiphagocytosis of RBCm@AuNPs-CP. After being coin-cubated RhoB-labeled RBCm@AuNPs with macrophages for 4 h, it was suggested by CLSM and FSM analysis that the red fluorescence was strong in macrophages in the AuNPs group, with an average fluorescence intensity of 3075 ± 256.3. While the same concentration of RBCm@AuNPs was incubated for the same time, the fluorescence in macrophages was decreased significantly, with a mean fluorescence intensity of 247.7 ± 62.4 (Figures 4(a) and 4(b)). The nanoplatform RBCm@AuNPs camouflaged by the red blood cell membrane could significantly reduce the recognition and clearance of nanoparticles by the monocyte-macrophage system and improve bioavailability.
3.4. Biocompatibility of Nanoplatforms. As shown in Figures 5(a) and 5(b), there was no distinct hemolysis (the hemolysis rate was less than 1%) after coincubation of erythrocytes with AuNPs or for 2 h, furthermore, the hemolysis rate of RBCm@AuNPs was lower than that of unmodified AuNPs. It was proved that the RBCm@AuNPs nanoplatform was well compatible in circulation and, therefore, was safe for intravenous administration into the blood.

3.5. In Vitro Antitumor Therapy of RBCm@AuNPs-CP. In vitro antitumor effect of RBCm@AuNPs-CP was detected by CCK-8 assay. As shown in Figure 6(a), the viability rates of B16-F10 cells treated with PBS, AuNPs, CP, AuNPs-CP, and RBCm@AuNPs-CP were 100.1 ± 3.9%, 95.2 ± 11.6%, 72.6 ± 18.3%, 35.4 ± 13.4%, and 30.2 ± 17.0%, respectively. Among them, the inhibition rate of melanoma cells by the traditional chemotherapeutic CP was only 17.4%, but the
constructed nanocomposite system RBCm@AuNPs-CP could inhibit 70.8% growth of the melanoma cells.

The results of the apoptosis analysis were also consistent with those of FCM. As shown in Figure 6(b), after RBCm@AuNPs-CP treated for 24 h, the early and late apoptosis rates of B16-F10 cells were 51.2% and 29.3%, respectively. This was significantly higher than 35.9% and 39.1% for AuNPs-CP, 26.4% and 20.7% for CP, and 7.6% and 4.8% for AuNPs. This showed that the biomimetic nanocarrier constructed in this study had a more prominent antitumor effect than the traditional CP and could induce apoptosis in a large number of melanoma cells.

3.6. RBCm@AuNPs-CP Induced ROS. In order to further explore the mechanism of RBCm@AuNPs-CP induced death in melanoma cells, the level of ROS in B16-F10 cells after differently treated was detected by FCM. As shown in Figure 7(a), it was found that RBCm@AuNPs-CP could increase the expression of ROS in cells (the positive rate was 85.5%), which was much higher than that treated by

---

**Figure 5:** Imaging (a) and hemolysis rate (b) of RBCs at various concentrations of AuNPs and RBCm@AuNPs at 37°C after 2 h. Different concentrations of RBCm@AuNPs and AuNPs (3.125 to 100 μg/mL) were mixed with 5% mouse erythrocyte suspension. Data are mean ± SD (n = 3).

**Figure 6:** In vitro antitumor efficiency of RBCm@AuNPs-CP. (a) Cell viability and (b) analysis of apoptosis rate by FCM of B16-F10 cells treated with PBS, AuNPs, CP, AuNPs-CP, and RBCm@AuNPs-CP for 24 h. Data are mean ± SD (n = 3). *P < 0.05 and **P < 0.01 vs. PBS.
CP alone (65.6%). As shown in Figure 7(b), RBCm@AuNPs-CP induced an increase in the expression of singlet oxygen with stronger green fluorescence in B16-F10 cells. These suggested that RBCm@AuNPs-CP might induce melanoma cells apoptosis through ROS oxidative stress damage.

3.7. Target-Aptility of RBCm@AuNPs. To probe the targetability of RBCm@AuNPs in vitro, the cellular uptake experiments of RBCm@AuNPs in B16-F10 were carried out. After coincubated RhoB-labeled RBCm@AuNPs and AuNPs with B16-F10 for 24 h, the red fluorescence was stronger in cells treated with RBCm@AuNPs than which in AuNPs groups, with an average fluorescence intensity of 4873.1 ± 2973.2 and 538.7 ± 62.1, respectively (Figures 8(a) and 8(b)).

To further evaluate the tumor targeting ability of RBCm@AuNPs camouflaged by erythrocyte membrane in vivo, Cy5-labeled AuNPs-CP and RBCm@AuNPs were injected into B16-F10 tumor-bearing mice via the tail vein. At different time periods, the distribution of nanocomplexes in mice was analyzed by in vivo imaging. As shown in Figure 8(c), both AuNPs and RBCm@AuNPs were distributed evenly throughout the body at 6 h. However, due to the immune evasion effect and the EPR effect of RBCm@AuNPs after red blood cell camouflage, the fluorescence intensity of RBCm@AuNPs was significantly higher than that of AuNPs at 24 h in tumor site.

After 24 hours, the major organs and tumors were taken out for additional imaging analysis of their fluorescence intensity, as shown in Figures 8(d) and 8(e). It was found that AuNPs mainly accumulated in the liver, lung, spleen, kidney, and tumor. In contrast, the fluorescence intensity of RBCm@AuNPs at the tumor site was 5.1 times higher than that of AuNPs ($P < 0.01$), and the accumulation of RBCm@AuNPs in other organs was also reduced.

The erythrocyte membrane camouflage nanocarriers RBCm@AuNPs had the ability to passively target tumors in vivo. This provided the possibility of effectively transport pharmaceuticals to tumor sites for antitumor effects.

3.8. In Vivo Antimelanoma Effects of RBCm@AuNPs-CP. To evaluate the antitumor effect of RBCm@AuNPs-CP, the tumor size of B16-F10 tumor-bearing mice treated with PBS, AuNPs, CP, AuNPs-CP, and RBCm@AuNPs-CP groups was dynamically observed and recorded. The tumor tissue was sectioned and stained with H&E. As shown in Figure 9(a), the tumor growth curves of the nanoparticle AuNPs group were similar to those of the control group, with tumor size 8.4 and 9.5 times larger after 14 days of treatment than before the initial treatment. On the 14th day of treatment with CP and AuNPs-CP alone, the tumor size was 4.2 times and 1.6 times than that before initial treatment, respectively, which inhibited the growth of tumors. It suggested that the RBCm@AuNPs-CP nanocomposites constructed significantly inhibited the growth of tumors, furthermore, the tumors showed a decreasing trend, which was 0.5 times than initial tumor size on the 14th day of treatment ($P < 0.01$). The body weight of the mice did not differ significantly between the groups, although it changed compared to the control group (Figure 9(b)). After the mice were sacrificed on D14, ex vivo representative tumor tissue was taken a picture (Figure 9(c)), which showed the same result that the tumor size of the RBCm@AuNPs-CP group was smaller than that of the control group. This indicated that the constructed AuNPs-CP nanoplatform exerts an excellent antimelanoma effect, and that RBCm@AuNPs-CP, camouflaged by the erythrocyte membrane, could further enhance antitumor effect as high pharmaceuticals concentration at the tumor site by evading from mononuclear macrophage system and EPR effect.

As shown in Figure 9(d), it could be found from the H&E staining of ex vivo tumor tissues that after RBCm@AuNPs-CP treatment, extensive and distinct cell damage, necrosis, and
Figure 8: Targeting ability of RBCm@AuNPs. (a) The cellular uptake ability of Rho B-labeled AuNPs and Rho B-labeled RBCm@AuNPs in B16-F10. (b) Fluorescence intensities of collected B16-F10 after treatment with AuNPs and RBCm@AuNPs, as quantified by FCM. (c) In vivo fluorescence images of B16-F10 xenograft model at 6 h, 24 h after intravenous injection of cy5-labeled RBCm@AuNPs and AuNPs. (d) Ex vivo bioluminescent images of the main organs and tumor at 24 h post injection. (e) Semiquantitative analysis of fluorescence intensity from tumor and other tissues. Data are mean ± SD (n = 3). **P < 0.01, and ***P < 0.001.
even lysis occurred at the tumor site. Different degrees of cell necrosis morphological characteristics appeared in tumor sites of the CP or AuNPs-CP treatment groups, while the PBS and AuNPs groups maintained the original morphological characteristics of the tumor tissue.

3.9. Biosafety of RBCm@AuNPs-CP. Since the constructed RBCm@AuNPs-CP nanocomposite is a heterologous substance, verifying its safety is crucial for its clinical application. This study verified the safety of RBCm@AuNPs-CP in terms of body weight and H&E staining of major tissues. As shown in Figure 9(b), no significant changes in animal body weight were found throughout the treatment period, provided that RBCm@AuNPs-CP had less systemic toxicity.

According to the H&E staining of major organ in melanoma mice after treatment (Figure 10), there was no distinct abnormality observed from micrographs in all treatment groups. RBCm@AuNPs-CPs showed good biocompatibility in vivo, which provided the possibility of further clinical applications.

4. Discussion

One of the important factors that make traditional nanodrug delivery systems difficult to apply in the clinic are heterogeneity, immunogenicity, and toxicity. Nanoparticles are easily recognized and eliminated by the mononuclear macrophage system and immune system in vivo; meanwhile, their particle size is too small to long-term retention in circulation as it is metabolized by the liver and/or kidney [12]. In our study, the red blood cell membrane camouflaged nanoparticles RBCm@AuNPs-CP constructed in a simple and economical way to reduce the clearance rate of the nanodrug delivery system by the mononuclear macrophage system and improve the therapeutic efficiency of the nanodrug.

CP is a commonly used chemotherapeutic pharmaceuticals for the treatment of melanoma. It exerts excellent anti-tumor effects by entering into cells to damage DNA and induce apoptosis in oxidatively damaged cells [13, 14]. However, the accompanying side effects limit its clinical application. Studies have found that in tumor sites, cisplatin seems
to be more likely to accumulate in the following specific sites, such as kidney, liver, neurons, and inner ear [15–17], resulting in nephrotoxicity [18], hepatotoxicity [19], neurotoxicity [20], and ototoxicity [21]. The biomimetic nanoparticles loaded with CP constructed in this study could target tumor site specifically through the EPR effect of the nanoparticles at tumor site, which greatly reduces its aggregation in the liver, kidney, and other sites. It provides the possibility of reducing the toxicity of CP. Subsequent experiments could also show that there was no distinct damage to vital organs after RBCm@AuNPs-CP treatment.

At present, the engineered nanodrugs that have been widely used in clinical antitumor therapy are mainly chemotherapeutic drugs in the form of liposomes, like cytarabine liposome injection (Dypocyt) [22] and doxorubicin (Doxil) [23]. Many of these drugs have been approved by the FDA and are widely used in clinical practice. Liposomal drug delivery represents a highly adaptable therapeutic platform, which could reduce the toxicity of chemotherapy drugs; however, it does not own tumor-targeting properties, resulting in low bioavailability [24]. Although new multifunctional nanoscale antitumor drugs are emerging in an endless stream, it is embarrassing to achieve clinical translation. The huge obstacle is their safety and immunogenicity. The RBCm-wrapped gold nanoparticle biomimetic drug delivery system constructed in this study completely retains the surface proteins of the RBCm. These characteristic proteins achieve its targeted and safe role, which provides the possibility of its later clinical transformation.

In this study, RBCm@AuNPs-CP treatment of melanoma cells was found to promote the expression of singlet oxygen, increase the level of ROS, and induce apoptosis in B16-F10 cells. ROS could cause DNA damage through lipid peroxidation, depletion of sulfhydryl groups, and induction of signal transduction pathways, resulting in apoptosis [6]. Mitochondria are one of the most important targets of oxidative stress, and ROS might affect mitochondrial respiratory function and lead to cellular dysfunction [25]. ROS cause mtDNA damage and lead to a decrease in mitochondrial permeability transition [26], thereby promoting mitochondrial rupture [27]. Mitochondrial rupture releases cytochrome C and procaspase-9 [28]. Activated caspase-9 then interacts with other caspases to activate caspase-3, caspase-6 and caspase-7, thereby inducing apoptosis [29].

5. Conclusion

The erythrocyte camouflage nanosystem RBCm@AuNPs-CP possessed excellent monodispersity and high drug loading rate. The red blood cell membrane wrapped on its surface could effectively escape the immune system with well EPR effect at the tumor site, so that it could be retained at the tumor site and reduce its concentration in the heart, liver, spleen, lung, kidney, and other tissues, which was passive tumor target-ability. Meanwhile, RBCm@AuNPs-CP promoted early apoptosis and necrosis of melanocytes by inducing oxidative stress damage. This makes RBCm@AuNPs-CP a potentially novel, safe, and effective targeted drug delivery system for the treatment of melanoma.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon reasonable request and with permission of Xiangya Hospital, Central South University.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

[1] E. Erdei and S. M. Torres, “A new understanding in the epidemiology of melanoma,” Expert Review of Anticancer Therapy, vol. 10, no. 11, pp. 1811–1823, 2010.
[2] P. T. Bradford, “Skin cancer in skin of color,” Dermatology Nursing, vol. 21, no. 4, p. 170, 2009.
[3] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: a Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.
[4] W. E. Damsky, L. E. Rosenbaum, and M. Bosenberg, “Decoding melanoma metastasis,” Cancers, vol. 3, no. 1, pp. 126–163, 2011.
[5] B. Lian, L. Si, C. Cui et al., “Phase II randomized trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma,” Clinical Cancer Research, vol. 19, no. 16, pp. 4488–4498, 2013.
[6] A. M. Florea and D. Busselberg, “Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects,” Cancers, vol. 3, no. 1, pp. 1351–1371, 2011.
[7] I. K. Domingo, A. Latif, and A. P. Bhavsar, “Pro-inflammatory signalling PRRopels cisplatin-induced toxicity,” International Journal of molecular sciences, vol. 23, no. 13, p. 7227, 2022.
[8] X. F. Zhang and S. Gurunathan, “Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy,” International Journal of Nanomedicine, vol. 11, pp. 3655–3675, 2016.
[9] D. M. Connor and A. M. Broome, “Gold nanoparticles for the delivery of cancer therapeutics,” Advances in Cancer Research, vol. 139, pp. 163–184, 2018.
[10] M. P. Monopoli, C. Aberg, A. Salvati, and K. A. Dawson, “Biomolecular coronas provide the biological identity of nanosized materials,” Nature Nanotechnology, vol. 7, no. 12, pp. 779–786, 2012.
[11] A. M. Alkilany and C. J. Murphy, “Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?,” Journal of Nanoparticle Research, vol. 12, no. 7, pp. 2313–2333, 2010.
[12] O. C. Farokhzad and R. Langer, “Impact of nanotechnology on drug delivery,” ACS Nano, vol. 3, no. 1, pp. 16–20, 2009.
[13] M. S. Davies, S. J. Berners-Price, and T. W. Hambley, “Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA,” Inorganic Chemistry, vol. 39, no. 25, pp. 5603–5613, 2000.
[14] A. Brozovic, A. Ambriovic-Ristov, and M. Osmak, “The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin,” Critical Reviews in Toxicology, vol. 40, no. 4, pp. 347–359, 2010.
[15] L. H. Einhorn, “Curing metastatic testicular cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 7, pp. 4592–4595, 2002.
[16] A. M. Breglio, A. E. Rusheen, E. D. Shide et al., “Cisplatin is retained in the cochlea indefinitely following chemotherapy,” Nature Communications, vol. 8, no. 1, p. 1654, 2017.
[17] V. Volarevic, B. Djokovic, M. G. Jankovic et al., “Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity,” Journal of Biomedical Science, vol. 26, no. 1, p. 25, 2019.
[18] A. Ruggiero, P. Ferrara, G. Attina, D. Rizzo, and R. Riccardi, “Renal toxicity and chemotherapy in children with cancer,” British Journal of Clinical Pharmacology, vol. 83, no. 12, pp. 2605–2614, 2017.
[19] B. Vincenzi, G. Armento, M. Spalato Ceruso et al., “Drug-induced hepatotoxicity in cancer patients – implication for treatment,” Expert Opinion on Drug Safety, vol. 15, no. 9, pp. 1219–1238, 2016.
[20] A. Chiorazzi, S. Semperboni, and P. Marmiroli, “Current view in platinum drug mechanisms of peripheral neurotoxicity,” Toxins, vol. 3, no. 3, pp. 304–321, 2015.
[21] A. Romano, M. A. Capozza, S. Mastrangelo et al., “Assessment and management of platinum-related ototoxicity in children treated for cancer,” Cancers, vol. 12, no. 5, p. 1266, 2020.
[22] S. Phuphanich, B. Maria, R. Braeckman, and M. Chamberlain, “A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study,” Journal of Neuro-Oncology, vol. 81, no. 2, pp. 201–208, 2007.
[23] Y. Barenholz, “Doxil® — The first FDA-approved nano-drug: Lessons learned,” Journal of Controlled Release, vol. 160, no. 2, pp. 117–134, 2012.
[24] D. E. Large, R. G. Abdelmessih, E. A. Fink, and D. T. Auguste, “Liposome composition in drug delivery design, synthesis, characterization, and clinical application,” Advanced Drug Delivery Reviews, vol. 176, article 113851, 2021.
[25] S. Y. Saad, T. A. Najjar, and M. Alashari, “Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogenal toxicity in rats,” Clinical and Experimental Pharmacology & Physiology, vol. 31, no. 12, pp. 862–867, 2004.
[26] G. Kroemer, N. Zamzami, and S. A. Susin, “Mitochondrial control of apoptosis,” Immunology Today, vol. 18, no. 1, pp. 44–51, 1997.
[27] D. R. Green, “Apoptotic pathways: the roads to ruin,” Cell, vol. 94, no. 6, pp. 695–698, 1998.
[28] M. A. Fuertes, C. Alonso, and J. M. Perez, “Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance,” Chemical Reviews, vol. 103, no. 3, pp. 645–662, 2003.
[29] J. C. Reed, “Apoptosis-based therapies,” Nature Reviews Drug Discovery, vol. 1, no. 2, pp. 111–121, 2002.